In sterile oily solution manufacturing, algestone acetophenide is dissolved in a pharmacopoeial fixed oil at the concentration used in a monthly injectable contraceptive product. Published labeling for one combination product lists 150 mg/mL algestone acetophenide with 10 mg/mL estradiol enanthate in an oily vehicle. Because the steroid is practically insoluble in water, the drug product is compounded as a single-phase lipophilic solution rather than as an aqueous suspension. The manufacturing sequence therefore centers on moisture-controlled dissolution, filtration of a high-viscosity oil phase, and terminal sterilization or validated aseptic filling. In production-scale compounding vessels, the oil is heated to reduce dynamic viscosity; jacket temperature control in the range of 40–60 °C is common for depot steroid oil dissolution, but the exact set point must be justified by solubility data and degradation profiling for this specific API. Stainless steel 316L vessels with a polished contact surface of Ra ≤ 0.8 µm are specified to limit surface adsorption and to permit validated cleaning after oil residues. Agitation at 15–25 rpm using a low-shear anchor impeller prevents vortexing and air entrapment while the API dissolves over several hours. Dissolution endpoint is confirmed by visual inspection and by HPLC assay against a qualified reference standard, with in-process specifications that include API content as percentage of label claim and moisture content of the oil phase below the limit stated in the batch record.

The oil vehicle is filtered through a sequence of a 0.45 µm prefilter and a 0.22 µm sterilizing-grade membrane only when viscosity and membrane compatibility permit. Published data for this specific configuration is limited, and filter manufacturers' chemical compatibility data for fixed oils or benzyl benzoate must be consulted before validation. When the oil phase viscosity exceeds the practical filtration range, aseptic assembly of pre-sterilized components and final filtration of the oil through a 0.22 µm cartridge under positive nitrogen pressure are used, with bubble point and pressure decay tests performed before and after filtration. Terminal moist heat sterilization of filled vials at 121 °C for 15 min is feasible only after forced degradation studies demonstrate that the steroid acetophenide ester remains within specification; otherwise, aseptic filling of already sterile-filtered oil into sterile Type I glass vials is required. Filling lines equipped with positive-displacement pumps or time-pressure dosing systems are preferred over rotary piston pumps when viscosity changes with temperature cause fill weight drift. In-process fill weight checks are conducted at intervals and compared with the registered overage allowance and USP <1> injectable product requirements. The finished oily solution is inspected for visible particulates by USP <790>. Syringability is characterized by glide force testing using ISO 11040-6 for prefilled syringes or by injection force measurement with a tensile test stand fitted with a 21-gauge needle; the acceptance limit is established during development and verified on stability. Because the API is dissolved in oil, subvisible particulate limits follow USP <788>, with the applicable monograph limit of not more than 25 particles/mL ≥10 µm and 3 particles/mL ≥25 µm for the finished injection. Endotoxin control is verified by USP <85>, and sterility is confirmed by USP <71> with a minimum 14-day incubation.

If Estradiol Enanthate Is Co-Formulated, Sterilization Order Changes

Co-formulation with estradiol enanthate introduces a second lipophilic steroid ester with different degradation sensitivity. In the monthly injectable contraceptive, the label concentration of algestone acetophenide is 150 mg/mL and estradiol enanthate is 10 mg/mL. The combined API load is dissolved in the oil phase; the dissolution order is determined by solubility and heat sensitivity. Algestone acetophenide is added first because it may require a longer residence time at elevated temperature to dissolve completely. Estradiol enanthate is added after the oil phase has been cooled to 35–40 °C, and the batch is stirred under nitrogen overlay to limit oxidative degradation. If the two steroids are added simultaneously, the longer heating period can increase free estradiol content and generate oxidative degradation products that would require additional qualification of unknown peaks under ICH Q3B. The terminal sterilization decision is altered by the presence of the estrogen ester: moist heat at 121 °C may be poorly tolerated, making aseptic filtration and aseptic filling the preferred route when the formulation contains estradiol enanthate. The oil phase is therefore filtered through a 0.45 µm prefilter and a 0.22 µm sterilizing-grade membrane before filling into sterile vials. Assay selectivity for the two steroids is achieved on a C18 reversed-phase HPLC column with a mobile phase gradient; peak purity is confirmed with a photodiode array detector, and the method is validated for specificity, linearity, accuracy, and precision according to ICH Q2(R1). Forced degradation studies in oil are performed under heat, oxidative stress, and hydrolytic conditions; published data for this specific combination is limited, so degradation product thresholds are established from development stability batches and safety qualification. In-process checks include free estradiol, total estradiol, and algestone acetophenide content, with limits that account for ester hydrolysis during storage at 2–8 °C or controlled room temperature as defined by the product license. The finished injection is tested for visible particulates by USP <790>, subvisible particulates by USP <788>, sterility by USP <71>, and bacterial endotoxins by USP <85>. Packaging in amber vials under nitrogen headspace is used to reduce photodegradation and oxygen ingress; headspace oxygen content is monitored and controlled below the limit justified during development.

Dry Granulation and Direct Compression of Micronized Progestin

Although published clinical data for oral algestone acetophenide are limited, a tablet or granule dosage form based on this lipophilic steroid requires the same solid-dose engineering controls as other poorly wettable progestins. The API is first characterized by laser diffraction particle sizing; a micronized steroid lot with a D90 between 5 µm and 15 µm is often specified when low-dose content uniformity is critical, but the acceptance range for this specific compound must be established from development batches because public data are limited. Direct compression is generally not the first-choice route for a low-dose, cohesive API because the drug may segregate in the hopper and yield weight variation. Dry granulation by roller compaction is preferred when the drug load is below 10% w/w and the API is sensitive to moisture or heat. The intragranular blend contains microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and colloidal silicon dioxide; the API is pre-blended with a portion of the diluent to form a trituration before the main blending step. A roller compactor with a gap width of 1–2 mm and a roll force that achieves ribbon solid fraction between 0.55 and 0.65 is a typical starting point for steroid granulations, but the exact parameters are optimized for the formulation. The granulated material is milled through a screen with an aperture of 0.8 mm to 1.0 mm and then blended with extragranular disintegrant and lubricant. Magnesium stearate is added at 0.5–1.0% w/w and blended for a fixed number of revolutions; overlubrication is controlled by monitoring bulk density and tablet hardness. The final blend is compressed on a rotary tablet press with a force feeder and pre-compression station. Tablet hardness is measured on a hardness tester, and friability is tested according to USP <1216>; a friability result above 1.0% after 100 revolutions indicates a need to adjust compression force or binder level. Content uniformity follows USP <905> with an acceptance value ≤ 15 for individual dosage units unless the label claim is below 10 mg or the drug load is below 10%, in which case the more stringent limits of the chapter apply. Dissolution testing uses USP <711> apparatus 2 with a paddle speed of 50 rpm and a surfactant-containing aqueous medium; the surfactant type and concentration are justified by solubility data because algestone acetophenide is practically insoluble in water. The tablet formulation is packaged in aluminum foil blisters with desiccant if moisture uptake studies show softening or degradation at accelerated conditions.

For capsule dosage forms, the same low-solubility and cohesive-flow constraints apply, but the unit operation changes from compression to encapsulation. On a dosator-type automatic capsule filler, powder plug formation is controlled by tamping pin depth and powder bed height; a high-dose algestone acetophenide blend without granulation may bridge in the hopper and produce weight variation outside USP <905> limits. The formulation is therefore either roller-compacted into granules or prepared as a pre-blend with lactose monohydrate and microcrystalline cellulose before filling. Empty hard gelatin shells are conditioned to a moisture content consistent with the manufacturer's specification, and the filling room is maintained at 40–45% RH to avoid shell brittleness or softening. Content uniformity is monitored at start-up and at defined intervals; stratified sampling across the powder bed is used because low-dose steroid blends can separate under vibration. The finished capsules are tested by USP <711> for dissolution and by USP <905> for uniformity of dosage units. Because published clinical data for oral algestone acetophenide are limited, dissolution acceptance criteria are derived from development batches and are not extrapolated from the injectable product. This capsule configuration is generally reserved for formulations where flexible oral dosing is required and the API has been shown to be stable in the presence of shell moisture and lubricants.

Which Stability-Indicating Parameters Govern an Oily Progestin Depot API?

When algestone acetophenide is released as a pharma-grade API for injectable compounding, the certificate of analysis must address residual solvents, elemental impurities, related substances, assay, loss on drying, and particle properties where relevant. The API is tested against in-house specifications aligned with ICH Q3C for residual solvents, ICH Q3D for elemental impurities, and ICH Q6A for specification justification. Residual solvent limits follow the permitted daily exposure values in ICH Q3C, while elemental impurity levels are controlled to the parenteral and oral concentration limits in ICH Q3D. The related substances method is stability-indicating and typically uses reversed-phase HPLC with UV detection; individual impurity limits are based on qualification thresholds in ICH Q3B. For the injectable dosage form, the finished product is tested for sterility by USP <71>, bacterial endotoxins by USP <85>, visible particulates by USP <790>, subvisible particulates by USP <788>, assay, related substances, and acid value where applicable. For an oily solution, a pH test is generally not applicable; the oil vehicle is instead characterized by acid value, peroxide value, and water content to control oxidation and hydrolytic degradation. The peroxide value of the oil is monitored against a limit justified by stability data because lipid peroxides can react with the steroid acetophenide. Stability studies follow ICH Q1A(R2) and include long-term, intermediate, and accelerated conditions; for an injectable product, orientation to final market climate is required, and the container closure system is qualified for integrity by dye ingress or vacuum decay. A release test for syringeability is included in the development report and, where required, in the finished product specification; it reports the force required to expel the solution through a needle of defined gauge at a specified rate. The API manufacturer's batch-to-batch variability in residual solvent profile and particle size can affect downstream oil dissolution time and filter loading; this is managed through a supplier quality agreement and incoming material inspection.

Starting-material qualification for downstream manufacturers is also a distinct application of pharma-grade algestone acetophenide. The API supplier's data must support the finished-dose dossier: batch-to-batch consistency of polymorphic form, residual solvent profile, particle-size distribution where relevant, and related substances. The manufacturing process described in the registration follows the ICH M4Q Common Technical Document structure and 21 CFR 211 current good manufacturing practice. Equipment cleaning validation is performed according to 21 CFR 211.67, and aseptic process simulation with media fills is carried out at intervals not exceeding 6 months. A commonly applied target for periodic process simulation is zero contaminated units in 5000 filled units, but the exact acceptance criterion follows regulatory risk assessment and site procedure. The API is released only after review of the certificate of analysis against the approved specification, and any deviation in residual solvent or particle size triggers a technical risk assessment because it can alter oil dissolution time or blend uniformity in downstream processing.